Methods of treating anemia using recombinant adeno-associated virus virions

Abstract

The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue in the treatment of anemia is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of a delivered nucleotide sequence encoding erythropoietin, and for in vivo secretion thereof from transduced muscle cells such that systemic delivery is achieved.

1 . A composition, comprising: 
 (a) recombinant AAV virions which comprise an AAV vector containing a nucleic acid molecule encoding erythropoietin operably linked to control elements that direct the transcription and translation thereof when present in a host cell; and    (b) a pharmaceutically acceptable excipient.    
     
     
         2 . A method of treating anemia in a mammalian subject, comprising introducing into a muscle cell or tissue of said subject in vivo a therapeutically effective amount of the pharmaceutical composition of  claim 1 .  
     
     
         3 . The method of  claim 2 , wherein the anemia is an anemic disorder selected from the group consisting of anemia associated with chronic renal failure, cancer, cancer chemotherapy and antiviral therapy.  
     
     
         4 . A method of treating a hemoglobinopathy in a mammalian subject, comprising introducing into a muscle cell or tissue of said subject in vivo a therapeutically effective amount of the pharmaceutical composition of  claim 1 .  
     
     
         5 . The method of  claim 4 , wherein the hemoglobinopathy is selected from the group consisting of sickle cell disease and thalassemia.  
     
     
         6 . The method of  claim 2 , wherein the muscle cell or tissue is derived from skeletal muscle.  
     
     
         7 . The method of  claim 6 , wherein the muscle cell is a skeletal myoblast.  
     
     
         8 . The method of  claim 6 , wherein the muscle cell is a skeletal myocyte.  
     
     
         9 . The method of  claim 2 , wherein the pharmaceutical composition is administered by intramuscular injection.  
     
     
         10 . The method of  claim 9 , wherein the pharmaceutical composition is administered in a single dose.  
     
     
         11 . The method of  claim 9 , wherein the pharmaceutical composition is administered in multiple doses.  
     
     
         12 . The method of  claim 2 , wherein the nucleic acid molecule encodes native human erythropoietin.  
     
     
         13 . The method of  claim 2 , wherein the nucleic acid molecule encodes native feline erythropoietin.  
     
     
         14 . The method of  claim 2 , wherein the control elements comprise a muscle-specific promoter sequence.  
     
     
         15 . The method of  claim 2 , wherein the control elements comprise an inducible promoter sequence.  
     
     
         16 . The method of  claim 2 , wherein the recombinant AAV virions are introduced to the subject in combination with an adjunctive pharmacological therapy.  
     
     
         17 . The method of  claim 16 , wherein the adjunctive pharmacological therapy comprises administering a therapeutically effective amount of an agent selected from the group consisting of hydroxyurea, butyrate, clotrimazole, and combinations thereof.  
     
     
         18 . A method of treating anemia in a mammalian subject comprising: 
 (a) introducing a recombinant AAV virion into a muscle cell in vitro to produce a transduced muscle cell, wherein said recombinant AAV virion comprises an AAV vector having a nucleic acid molecule encoding erythropoietin operably linked to control elements that direct the transcription and translation thereof when present in said subject; and    (b) administering to said subject a therapeutically effective amount of a composition comprising a pharmaceutically acceptable excipient and the transduced muscle cells or tissue from step (a).    
     
     
         19 . The method of  claim 18 , wherein the anemia is an anemic disorder selected from the group consisting of anemia associated with chronic renal failure, cancer, cancer chemotherapy and antiviral therapy.  
     
     
         20 . The method of  claim 18 , wherein the anemia is a hemoglobinopathy.  
     
     
         21 . The method of  claim 20 , wherein the hemoglobinopathy is selected from the group consisting of sickle cell disease and thalassemia.  
     
     
         22 . The method of  claim 18 , wherein the muscle cell is derived from skeletal muscle.  
     
     
         23 . The method of  claim 22 , wherein the muscle cell is a skeletal myoblast.  
     
     
         24 . The method of  claim 22 , wherein the muscle cell is a skeletal myocyte.  
     
     
         25 . The method of  claim 18 , wherein the nucleic acid molecule encodes native human erythropoietin.  
     
     
         26 . The method of  claim 18 , wherein the nucleic acid molecule encodes native feline erythropoietin.  
     
     
         27 . The method of  claim 18 , wherein the control elements comprise a muscle-specific promoter sequence.  
     
     
         28 . The method of  claim 18 , wherein the control elements comprise an inducible promoter sequence.  
     
     
         29 . A method for delivering a therapeutically effective amount of erythropoietin systemically to a mammalian subject in vivo comprising introducing into a muscle cell or tissue of said subject the pharmaceutical composition of  claim 1 .  
     
     
         30 . The method of  claim 29 , wherein the nucleic acid molecule encodes native human erythropoietin.  
     
     
         31 . The method of  claim 29 , wherein the nucleic acid molecule encodes native feline erythropoietin.  
     
     
         32 . A method for delivering a therapeutically effective amount of erythropoietin systemically to a mammalian subject comprising: 
 (a) introducing a recombinant AAV virion into a muscle cell in vitro to produce a transduced muscle cell, wherein said recombinant AAV virion comprises an AAV vector having a nucleic acid molecule encoding erythropoietin operably linked to control elements that direct the transcription and translation thereof when present in said subject; and    (b) administering to said subject a therapeutically effective amount of a composition comprising a pharmaceutically acceptable excipient and the transduced muscle cells from step (a).    
     
     
         33 . The-method of  claim 32 , wherein the nucleic acid molecule encodes native human erythropoietin.  
     
     
         34 . The method-of  claim 32 , wherein the nucleic acid molecule encodes native feline erythropoietin.